- Home
- CDNS vs BMY Comparison
CDNS vs BMY Comparison
Compare CDNS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNS
- BMY
- Stock Information
- Founded
- CDNS 1988
- BMY 1887
- Country
- CDNS United States
- BMY United States
- Employees
- CDNS N/A
- BMY N/A
- Industry
- CDNS Computer Software: Prepackaged Software
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- CDNS Technology
- BMY Health Care
- Exchange
- CDNS Nasdaq
- BMY Nasdaq
- Market Cap
- CDNS 95.3B
- BMY 94.0B
- IPO Year
- CDNS 1987
- BMY N/A
- Fundamental
- Price
- CDNS $351.52
- BMY $46.37
- Analyst Decision
- CDNS Strong Buy
- BMY Hold
- Analyst Count
- CDNS 15
- BMY 15
- Target Price
- CDNS $360.33
- BMY $57.64
- AVG Volume (30 Days)
- CDNS 1.6M
- BMY 9.6M
- Earning Date
- CDNS 10-27-2025
- BMY 10-30-2025
- Dividend Yield
- CDNS N/A
- BMY 5.35%
- EPS Growth
- CDNS N/A
- BMY N/A
- EPS
- CDNS 3.70
- BMY 2.49
- Revenue
- CDNS $5,089,287,000.00
- BMY $47,704,000,000.00
- Revenue This Year
- CDNS $15.31
- BMY N/A
- Revenue Next Year
- CDNS $12.13
- BMY N/A
- P/E Ratio
- CDNS $94.99
- BMY $18.65
- Revenue Growth
- CDNS 22.30
- BMY 2.57
- 52 Week Low
- CDNS $221.56
- BMY $42.96
- 52 Week High
- CDNS $376.45
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- CDNS 52.04
- BMY 44.49
- Support Level
- CDNS $326.35
- BMY $45.85
- Resistance Level
- CDNS $357.76
- BMY $48.19
- Average True Range (ATR)
- CDNS 9.31
- BMY 0.89
- MACD
- CDNS -0.81
- BMY -0.11
- Stochastic Oscillator
- CDNS 69.22
- BMY 19.36
About CDNS Cadence Design Systems Inc.
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enables system-level analysis and verification solutions.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.